Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$56.13−0.03 (-0.05%)
Close on Nov 13, 2026Market cap $7.80BP/E –Yield –
Cytokinetics r&d expenses
Research and development expenses are spending on new products and technology.
Cytokinetics's R&D Expenses for the twelve months ending Sep 30, 2026 was $402.95M, up 0.9% year over year. For fiscal 2025 it was $416.03M, up 22.6% from the year before. Over ten years it grew 24.5% a year on average. The highest annual figure on record is $416.03M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $416.03M | +22.6% |
| FY2024 | Dec 31, 2024 | $339.41M | +2.8% |
| FY2023 | Dec 31, 2023 | $330.12M | +37.1% |
| FY2022 | Dec 31, 2022 | $240.81M | +50.6% |
| FY2021 | Dec 31, 2021 | $159.94M | +65.0% |
| FY2020 | Dec 31, 2020 | $96.95M | +12.6% |
| FY2019 | Dec 31, 2019 | $86.13M | -3.4% |
| FY2018 | Dec 31, 2018 | $89.14M | -1.3% |
| FY2017 | Dec 31, 2017 | $90.30M | +50.8% |
| FY2016 | Dec 31, 2016 | $59.90M | +29.1% |
| FY2015 | Dec 31, 2015 | $46.40M | +4.4% |
| FY2014 | Dec 31, 2014 | $44.43M | -10.2% |
| FY2013 | Dec 31, 2013 | $49.45M | +38.7% |
| FY2012 | Dec 31, 2012 | $35.64M | -4.1% |
| FY2011 | Dec 31, 2011 | $37.18M | -2.2% |
| FY2010 | Dec 31, 2010 | $38.01M | -4.6% |
| FY2009 | Dec 31, 2009 | $39.84M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $99.29M | +2.0% |
| Q2 FY2026 | Jun 30, 2026 | $97.81M | -11.2% |
| Q1 FY2026 | Mar 31, 2026 | $95.53M | -2.8% |
| Q4 FY2025 | Dec 31, 2025 | $110.33M | +17.8% |
| Q3 FY2025 | Sep 30, 2025 | $97.30M | +15.0% |
| Q2 FY2025 | Jun 30, 2025 | $110.14M | +38.4% |
| Q1 FY2025 | Mar 31, 2025 | $98.26M | +20.5% |
| Q4 FY2024 | Dec 31, 2024 | $93.63M | +10.2% |
| Q3 FY2024 | Sep 30, 2024 | $84.61M | +2.5% |
| Q2 FY2024 | Jun 30, 2024 | $79.60M | -4.3% |
| Q1 FY2024 | Mar 31, 2024 | $81.57M | +2.7% |
| Q4 FY2023 | Dec 31, 2023 | $84.98M | +13.3% |
| Q3 FY2023 | Sep 30, 2023 | $82.53M | +31.6% |
| Q2 FY2023 | Jun 30, 2023 | $83.19M | +45.6% |
| Q1 FY2023 | Mar 31, 2023 | $79.42M | +72.9% |
| Q4 FY2022 | Dec 31, 2022 | $75.02M | +72.5% |
| Q3 FY2022 | Sep 30, 2022 | $62.73M | +29.5% |
| Q2 FY2022 | Jun 30, 2022 | $57.13M | +56.8% |
| Q1 FY2022 | Mar 31, 2022 | $45.94M | +45.5% |
| Q4 FY2021 | Dec 31, 2021 | $43.50M | +48.9% |
| Q3 FY2021 | Sep 30, 2021 | $48.44M | +100.1% |
| Q2 FY2021 | Jun 30, 2021 | $36.44M | +67.2% |
| Q1 FY2021 | Mar 31, 2021 | $31.56M | +45.2% |
| Q4 FY2020 | Dec 31, 2020 | $29.22M | +59.4% |
| Q3 FY2020 | Sep 30, 2020 | $24.20M | +19.6% |
| Q2 FY2020 | Jun 30, 2020 | $21.79M | -9.3% |
| Q1 FY2020 | Mar 31, 2020 | $21.74M | -7.7% |
| Q4 FY2019 | Dec 31, 2019 | $18.33M | -21.2% |
| Q3 FY2019 | Sep 30, 2019 | $20.23M | -5.4% |
| Q2 FY2019 | Jun 30, 2019 | $24.02M | +11.3% |
| Q1 FY2019 | Mar 31, 2019 | $23.55M | +6.4% |
| Q4 FY2018 | Dec 31, 2018 | $23.28M | -11.3% |
| Q3 FY2018 | Sep 30, 2018 | $21.39M | -14.3% |
| Q2 FY2018 | Jun 30, 2018 | $21.58M | +9.0% |
| Q1 FY2018 | Mar 31, 2018 | $22.14M | +14.8% |
| Q4 FY2017 | Dec 31, 2017 | $26.25M | +39.8% |
| Q3 FY2017 | Sep 30, 2017 | $24.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $19.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $18.78M | – |
See a number that looks wrong?